中性粒细胞胞外诱捕网在腹主动脉瘤中的研究进展

腹主动脉瘤(AAA)的发病机制复杂, 包括动脉硬化、血流动力学和遗传等多种因素。中性粒细胞在AAA发生发展过程中扮演重要角色, 但具体机制尚未明确。中性粒细胞胞外诱捕网(NETs)是由中性粒细胞发生程序性死亡后释放至胞外参与诱捕细菌的网格样结构。研究结果显示中性粒细胞通过释放NETs参与炎性反应及AAA病理生理过程。本文对NETs参与AAA发生发展的机制研究进行综述。     

椎间盘退变中微小RNA及其非病毒载体的研究进展

目的总结椎间盘退变(intervertebral disc degeneration,IDD)中微小RNA(micro RNA,mi RNA)及其非病毒载体的研究进展,探讨非病毒载体递送mi RNA的临床应用潜能,为IDD治疗提供新思路。方法广泛查阅国内外有关mi RNA在IDD中作用及其非病毒载体相关的文献并进行总结分析。结果退变椎间盘组织中明显差异性表达的mi RNA通过对基因表达的调控参与多种病理生理过程,许多类型非病毒载体递送mi RNA的基因治疗方式在一些疾病治疗中已取得了理想效果。结论 mi RNA在IDD细胞分子机制中发挥重要作用,非病毒载体作为一种安全有效的基因治疗策略,为通过mi RNA治疗IDD提供了新的可能。     

ADAM9在乳腺癌中的表达及意义

目的探讨去整合素金属蛋白酶9(ADAM9)在乳腺癌中的表达及意义。方法采用逆转录多聚酶链聚合反应(RT-PCR)法和免疫组织化学方法检测乳腺癌组织、距离癌旁≥5cm的正常乳腺组织及腋窝淋巴结组织中ADAM9的表达,并分析ADAM9表达与乳腺癌临床病理特征之间的关系。结果 ADAM9mRNA在乳腺癌组织中的表达较正常乳腺组织(未检测到ADAM9mRNA的表达)明显增强。ADAM9蛋白表达阳性率在乳腺癌组织中明显高于正常乳腺组织(P0.05),其在乳腺癌转移淋巴结中的表达明显高于非转移淋巴结及相应原发灶中的表达(P0.05).乳腺癌组织中ADAM9蛋白表达阳性率与其淋巴结转移和组织学分级有关(P0.05).结论ADAM9在乳腺癌中表达上调,可能参与了乳腺癌发生、发展过程。     

ADAM12在原发性肝癌侵袭性中的作用及机制研究

目的观察ADAM12在原发性肝癌组织中的表达及与预后的关系,探讨ADAM12调控肝癌细胞的侵袭转移的作用及机制。方法采用免疫组化检测ADAM12和上皮-间充质转化(epithelial-mesenchymal transition,EMT)标志物在肝癌组织中的表达,统计分析对应原发性肝癌病人的预后情况。培养HepG2、MHCC97H肝癌细胞系,病毒转染,构建稳定的ADAM12沉默和过表达细胞。CCK8检测ADAM12对癌细胞增殖的影响,Transwell实验检测ADAM12对肝癌细胞侵袭能力的影响。Western Blot检测肝癌细胞中ADAM12和EMT标志物的表达改变。结果 ADAM12表达水平越高,肝癌病人的预后可能越差,肿瘤≥3 cm可能性越大,分化程度越低,TNM分期越晚,肿瘤Ki67指数越高,且有统计学意义(P0.05)。ADAM12的表达水平越高,肝癌增殖能力越大(P0.05),抑制ADAM12的表达可降低肝癌细胞的增殖能力(P0.05)。ADAM12的表达水平越高,肝癌侵袭潜能越大(P0.05),抑制ADAM12的表达可抑制肝癌的侵袭(P0.05),而过表达ADAM12可促进肝癌的侵袭(P0.05)。ADAM12的表达水平与EMT标志物E-cadherin、N-cadherin、Vimentin的表达有关(P0.05)。结论 ADAM12通过调控肝癌EMT,增强HepG2、MHCC97H肝癌细胞增殖、侵袭能力。通过抑制ADAM12,可抑制肝癌细胞EMT,降低HepG2、MHCC97H肝癌细胞增殖、侵袭能力。     

脊索瘤中microRNA的差异性表达及其RNA编辑

目的 :检测脊索瘤组织中micro RNA(mi RNA)的差异性表达情况,探讨其RNA编辑。方法 :使用RTq PCR(Real-time quantitative polymerase chain reaction)技术检测骶骨脊索瘤组织11种候选mi RNA的表达水平,将其与髓核组织中的表达水平进行比较,对表达异常的mi RNA前体(pri-mi RNAs)的DNA和c DNA序列进行对比,检测是否存在RNA编辑。使用蛋白印迹法(Western blot)检测脊索瘤组织中RNA编辑的关键酶RNA腺苷脱氨酶(adenosine deaminase acting on RNA,ADARs)的表达。构建ADAR的表达载体,同时构建ERBB2和HOXA1的3′-非翻译区报告载体并转染mi RNA模拟物和抑制物,将其和ADAR的表达载体共转染至人胚肾细胞293T(HEK293T细胞),用q RT-PCR检测mi RNA的表达水平,并通过荧光素酶报告基因活性分析法对已测得异常表达的mi RNA的靶基因ERBB2和HOXA1进行活性分析,检测ADAR与测得异常表达的mi RNA的靶基因的关系。结果:与髓核组织相比,脊索瘤组织中mi R-10a和mi R-125a的相对表达程度明显下调(P<0.05)。脊索瘤组织中mi R-10a和mi R-125a的前体c DNA序列中出现了腺苷酸向鸟苷酸(A-G)突变,而在髓核组织中mi R-10a和mi R-125a前体的c DNA序列中无此改变,mi R-10a和mi R-125a在成熟过程中出现了A-I RNA编辑。4组脊索瘤组织中有3组存在ADAR1过度表达,2组存在ADAR2过度表达。转染了mi RNA抑制物的HEK293T细胞中ADAR1表达出现上调,而mi R-10a和mi R-125a的表达出现下调,mi R-10a的靶基因ERBB2和mi R-125a的靶基因HOXA1的荧光素酶活性显著增高;相反,转染了mi RNA模拟物的HEK293T细胞中ADAR1表达出现下调,而mi R-10a和mi R-125a的表达出现上调,ERBB2和HOXA1的荧光素酶活性显著降低。结论:ADAR1的过度表达可能通过介导A-I RNA编辑影响mi R-10a和mi R-125a的成熟和表达,参与脊索瘤发生中的细胞异常增殖调控。     

ADAM17-shRNA通过Akt/GSK3β信号通路促进HT29结肠癌细胞的凋亡

目的探讨沉默解聚素-金属蛋白酶17(ADAM17)基因的表达对HT29结肠癌细胞增殖和凋亡的抑制作用及其可能机制。方法将HT29结肠癌细胞分为干扰组、阴性对照组和空白对照组,干扰组细胞转染重组慢病毒载体以沉默ADAM17基因的表达,阴性对照组细胞转染阴性对照重组慢病毒载体,空白对照组细胞加入等量的PBS溶液。采用实时荧光定量PCR法(real-time PCR)检测ADAM17 mRNA的表达,采用Western blot法检测ADAM17、半胱氨酸天冬氨酸蛋白酶-3(caspase3)、磷酸化蛋白激酶B(P-Akt)、蛋白激酶B(Akt)、磷酸化糖原合成酶激酶-3β(P-GSK3β)及糖原合成酶激酶-3β(GSK3β)蛋白的表达,采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法检测细胞增殖能力的变化,采用Annexin-V-FITC/PI试剂盒检测细胞凋亡情况。结果与阴性对照组和空白对照组比较,干扰组细胞中ADAM17 mRNA及其蛋白的表达水平均较低,同时点(培养24、48及72 h)的吸光度值(A值)也较低,细胞凋亡率较高,caspase3蛋白的表达水平较高,P-Akt和P-GSK3β蛋白的表达水平均较低,差异均有统计学意义(P0.05)。结论 ADAM17基因沉默可能通过抑制Akt/GSK3β通路的激活,发挥抑制细胞增殖和诱导细胞凋亡的作用。     

非小细胞肺癌细胞A549顺铂耐药潜在机制的全转录组测序分析

目的通过全转录组测序分析比较野生型A549细胞和顺铂耐药A549细胞(A549/DPP)表达谱的差别,揭示非小细胞肺癌(NSCLC)顺铂耐药潜在机制。方法首先建立A549/DDP细胞系,对A549和A549/DDP进行全转录组测序,分别对lnc RNA-seq,circ RNA-seq和mi RNA-seq数据进行差异表达以及功能富集分析(KEGG和GO分析)。然后进行全转录组数据联合分析以及ce RNA网络的构建。结果与A549细胞系相比,其中4517个lnc RNA、123个circ RNA以及145个mi RNA在A549/DDP细胞中有差异表达。显著富集在与癌症相关的通路上。mi RNA-circ RNA-lnc RNA-m RNA四元网络包含了12个mi RNA,4个circ RNA,23个lnc RNA和9个m RNA节点。经过拓扑学性质分析hsa-mi R-125a-5p和hsa-mi R-125b-5p是顺铂耐药相关的关键mi RNA。结论肿瘤坏死因子信号通路和p53信号通路参与了A549/DPP耐药机制。Hsa-mi R-125a-5p和hsa-mi R-125b-5p可能是逆转顺铂抗性的潜在靶点。     

人脂肪来源干细胞成软骨分化过程中成软骨相关微小RNA表达的初步研究

目的探讨微小RNA(micro RNA,mi RNA)在人脂肪来源干细胞(human adipose-derived stem cells,h ADSCs)诱导成软骨分化过程中的表达规律及其影响软骨分化的可能机制。方法取行抽脂术或其他腹部手术患者自愿捐赠的脂肪组织,分离、培养h ADSCs并鉴定。取第3代细胞成软骨分化,倒置相差显微镜下观察细胞形态,于诱导21 d行阿尔新蓝染色观察软骨形成情况,诱导0、7、14、21 d行ELISA检测成软骨相关蛋白Ⅱ型胶原蛋白(collagen typeⅡ,Col2a1)、蛋白聚糖(Aggrecan)、Col10a1以及硫酸软骨素表达。采用基因芯片技术筛选h ADSCs成软骨诱导前及诱导后21 d差异性表达mi RNA,并预测筛选出的mi RNA靶基因。结果实验成功培养h ADSCs,经成软骨诱导培养后,随时间延长可形成软骨球;21 d阿尔新蓝染色呈阳性;h ADSCs成软骨诱导后7、14、21 d,Col2a1、Aggrecan、Col10a1及硫酸软骨素表达水平均较成软骨诱导前h ADSCs显著增高,差异均有统计学意义(P0.05)。基因芯片技术共筛选出11个差异性表达mi RNA,其中7个mi RNA表达上调,4个mi RNA表达下调。筛选出的成软骨相关mi RNAs预测靶基因可能参与了干细胞成软骨分化、增殖、凋亡、细胞周期调控,以及介导细胞内级联反应和自我更新等。结论实验筛选出11个成软骨分化差异性表达超过2倍的mi RNAs,并对其靶基因进行预测,加深了对h ADSCs成软骨分化机制的理解,为定向控制h ADSCs成软骨分化及筛选组织工程改良种子细胞提供了理论依据。     

男性不育症患者精液ADAM基因表达的临床意义

目的探讨ADAM(去整合素和金属蛋白酶区家族)基因与不明原因不育症之间的关系。方法应用RT-PCR方法检测30例正常生育男性和30例不明原因不育症患者精液中ADAM1、ADAM2、ADAM3、ADAM32基因的 mRNA表达。结果正常组30例中4种基因 mRNA均有表达,不育组30例中有1例ADAM1、2、32呈阴性表达,1例ADAM2、32呈阴性表达,ADAM1和ADAM3呈阴性表达各1例,26例4种基因均呈阳性表达。结论ADAM1、2、3、32基因缺失或不表达可能是导致不育的候选基因之一。     

独活寄生汤通过miRNAs调控炎症性骨关节炎软骨细胞功能改变的机制探讨

软骨细胞功能改变在骨关节炎病理过程中发挥重要的调控作用。炎症因子是介导骨关节炎软骨退变的主要因素,其表达与Micro RNAs(mi RNAs)密切相关。mi RNAs是一类在转录后水平调控基因表达的非编码蛋白的RNA分子,参与了软骨细胞增殖、分化,以及合成与分解代谢等生物学过程。中医药治疗骨关节炎独具特色,能够靶向调节mi RNAs介导的炎症反应,独活寄生汤长期运用于临床,能有效抑制关节炎症,其药效机制可能是通过调节骨关节炎软骨细胞中mi RNAs的表达,以及改变mi RNAs和炎症因子之间的相互协调作用而发挥对炎症性骨关节炎的治疗作用。多层次、多角度地探讨独活寄生汤的作用机制及药效物质基础,可为阐明独活寄生汤治疗炎症性骨关节炎提供新的研究思路。     

ADAM12-S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation.

ADAM12-S transgenic mice exhibit a pronounced increase in the length of bones, such as femur, tibia, and vertebrae. The effect of ADAM12-S on longitudinal bone growth involves the modulation of chondrocyte proliferation and maturation, likely through proteolytic activities and altered cell-extracellular matrix interactions in the growth plate. INTRODUCTION: The disintegrin and metalloprotease ADAM12 is expressed in both osteoblasts and osteoclasts, suggesting a regulatory role of ADAM12 in bone. However, thus far, no in vivo function of ADAM12 in the skeleton has been reported. MATERIALS AND METHODS: Transgenic mice expressing the secreted form of human ADAM12, ADAM12-S, or a truncated metalloprotease-deficient form of ADAM12-S in the circulation were used to study the effects of ADAM12 on the skeleton. In addition, murine chondrocyte cultures were used to study the effect of ADAM12-S on cell-extracellular matrix interactions. RESULTS: ADAM12-S transgenic mice exhibit increased longitudinal bone growth. The increased bone length is progressive and age dependent, with a maximum increase of 17% seen in the femur from 6-month-old transgenic mice. The effect is gene dose dependent, being more pronounced in mice expressing higher levels of the transgene than in a lower-expressing line. Histological analysis revealed no alterations in the growth plate organization, but mean growth plate width was increased. Both the cellular incorporation of bromodeoxyuridine and the width of the collagen type X-positive hypertrophic zone were increased in the growth plate of ADAM12-S transgenic mice. Importantly, mice expressing a truncated form of ADAM12-S that lacked the pro- and metalloprotease domains showed no alterations in bone length, suggesting that protease activity is required for the ADAM12-S effect. In vitro studies showed that ADAM12-S inhibits chondrocyte adhesion to fibronectin and collagen type II. CONCLUSIONS: ADAM12-S stimulates bone growth in mice by modulating chondrocyte proliferation and maturation through mechanisms probably involving both metalloprotease and adhesion activities.     

Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney

The chemokine CXCL16 plays an important role in the recruitment of leukocytes to sites of inflammation influencing the course of experimental glomerulonephritis. Here we show that human kidneys highly express CXCL16 in the distal tubule, connecting tubule and principal cells of the collecting duct with weak expression in the thick ascending limb of Henle. Beside the membrane localization, a soluble form of CXCL16 can be proteolytically released which acts as a chemotactic factor. In human renal tissue the expression pattern of the disintegrin-like metalloproteinase ADAM10 is similar to that of CXCL16, suggesting ADAM10 can potentially cleave CXCL16 in vivo. When we tested this in primary tubular cells we found that blockade of ADAM10 activity inhibited the IFN-gamma induced release of soluble CXCL16. Acute tubular damage in renal allografts was associated with elevated urinary CXCL16 and this correlated with focally increased apical CXCL16 expression in the distal tubules and collecting ducts. Renal allograft biopsies, with a histopathological diagnosis of acute interstitial rejection, showed increased basolateral ADAM10 expression together with high numbers of infiltrating T cells. Our results suggest that CXCL16 and ADAM10 are involved in the recruitment of T cells to the kidney and play an important role in inflammatory kidney diseases.     

骨保护素在腹主动脉瘤中的表达及作用

目的：探讨骨保护素（OPG）的表达在腹主动脉瘤（AAA）形成中的作用。方法：收集20例AAA组织和6例正常腹主动脉组织,用补片法构建兔AAA动物模型（18只AAA模型动物分别于造模后7,21,35 d取材,以6只假手术兔为对照）。用免疫组化法检测OPG在人AAA组织与正常腹主动脉组织中的表达;Western blot和RT-PCR法检测上述组织以及动物模型AAA组织中OPG、基质金属蛋白酶9（MMP-9）蛋白及mRNA的表达;末端转移酶标记（TUNEL）法观察动物模型AAA组织中膜血管平滑肌细胞（VSMC）的凋亡情况。结果：免疫组化显示,人AAA组织中OPG蛋白表达量较正常腹主动脉组织增加,且随AAA直径的增大而增加,在破裂性AAA组织中表达量最高。Western blot和RT-PCR结果显示,OPG与MMP-9蛋白及mRNA的表达在人AAA组织及动物模型AAA组织组均较各自的对照组明显升高（P<0.05）,且两者的蛋白与mRNA表达水平均随瘤体直径的增加或造模时间的延长而逐渐增加。TUNEL染色显示模型组VSMC凋亡细胞较对照组明显增加,且随造模时间延长有增加趋势（P<0.05）。结论：OPG表达水平与AAA的发生发展密切相关,机制可能与其促进MMP的表达和诱导VSMC凋亡有关。

     

Circular RNA circ_0114876 regulates osteoarthritis through upregulating ADAM10 via targeting miR-1227-3p

BackgroundOsteoarthritis (OA) was a chronic degenerative joint disease. The dysregulation of circular RNAs (circRNAs) has been identified in OA progression. However, the function and regulation mechanism of circ_0114876 in OA remains largely unknown.MethodFirstly, we used LPS-treated C28/I2 cells as a cellular model of OA. Quantificational real-time polymerase chain reaction (qRT-PCR) was used to determine the expression levels of circ_0114876, miRNA-1227-3p, and ADAM10 in OA chondrocytes. Cell Counting Kit-8 (CCK8), 5-ethynyl-20-deoxyuridine (EdU) incorporation assays, flow cytometry, Enzyme-linked immunosorbent assay (ELISA) kit, and western blot were applied to confirm cell proliferation, apoptosis, inflammation, and extracellular matrix.of circ_0114876 in vitro. The interaction between circ_0114876 and its downstream target (miR-1227-3p) and mRNA target ADAM metallopeptidase domain 10 (ADAM10), was evaluated by luciferase assay and RNA immunoprecipitation (RIP) assay.ResultCirc_0114876 and ADAM10 were upregulated and miR-1227-3p was decreased in OA tissues and LPS-treated chondrocytes. Low expression of circ_0114876 promoted proliferation and inhibited apoptosis, inflammation, and extracellular matrix of the LPS-treated chondrocytes. Mechanistically, circ_0114876 functioned in human chondrocytes through targeting miR-1227-3p and ADAM10. Furthermore, miRNA-1227-3p inhibitor reversed the effect of circ_0114876 knockdown on the OA chondrocytes, and ADAM10 overexpression reversed the effect of miR-1227-3p mimic on the OA chondrocytes.ConclusionCirc_0114876 was increased in OA tissues and cells. Circ_0114876 facilitated the progression in the LPS-induced OA cell model via regulating the miR-1227-3p/ADAM10 axis. This study would provide a potentially effective therapeutic strategy for OA progression.     

去整合素和金属蛋白酶17调控胰腺癌细胞增殖凋亡的机制

目的 探讨去整合素和金属蛋白酶17(ADAM17/TACE)调控胰腺癌细胞增殖凋亡的作用机制.方法 分别采用免疫组织化学及流式细胞仪检测58例胰导管腺癌组织及6株胰腺癌细胞株中ADAM 17/TACE的表达,用小RNA干扰(siRNA)技术去除胰腺癌细胞L3.6pl ADAM17/TACE mRNA及蛋白表达后,CCK-8试剂盒检测胰腺癌细胞L3.6pl的生长速度,Western blot检测ADAM17/TACE、凋亡相关基因PARP、增殖相关基因p27( p27kipl)表达.阻断表皮生长因子受体(EGFR)及丝氨酸苏氨酸蛋白激酶(AKT)通路后,Western blot检测ADAM17/TACE及EGFR/p-EGFR、AKT/p-AKT的表达变化.结果 58例胰导管腺癌组织及6株胰腺癌细胞中ADAM17/TACE的表达阳性率均为100％.同亲代L3.6pl细胞比较,siRNA干扰ADAM17/TACE mRNA的表达后,L3.6pl细胞生长速度减缓(P＜0.05);p27kipl的表达明显增强;多聚二磷酸腺苷核糖聚合酶(PARP)表达亦明显增强提示出现凋亡;分别阻断EGFR和磷脂酰肌醇3激酶(PI3K)/AKT信号通路后,ADAM17/TACE蛋白表达均增加.结论 ADAM 17/TACE调控胰腺癌细胞增殖,抑制其表达可致胰腺癌细胞凋亡,可能与PI3K/AKT信号通路相关.     

Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction

ObjectivesExtracellular matrix (ECM) remodelling is a critical aspect of cardiac remodelling following myocardial infarction. Tissue inhibitors of metalloproteinases (TIMPs) are physiological inhibitors of matrix metalloproteinases (MMPs) that degrade the ECM proteins. TIMP-3 is highly expressed in the heart and is markedly downregulated in patients with ischaemic cardiomyopathy. Cell-based gene therapy can enhance the effects of cell transplantation by temporally and spatially regulating the release of the gene product. The purpose of this study was to investigate the role of TIMP-3 gene-transfected vascular smooth muscle cells (VSMCs) in modifying heart structure and function in rats when transplanted 3 days after myocardial infarction (MI).MethodsAnesthetised rats were subjected to coronary artery ligation followed 3 days later by thoracotomy and transplantation of TIMP-3 gene-transfected VSMCs, untransfected VSMCs or medium injected directly into the ischaemic myocardium. We assessed left ventricular structure and function by echocardiography and morphometry, and measured the levels of myocardial matrix metalloproteinase-2 and -9 (MMP-2, MMP-9), TIMP-3 and tumour necrosis factor-α (TNF-α) at 4 weeks post-myocardial infarction.ResultsTransplantation of TIMP-3 gene-transfected VSMCs and untransfected VSMCs significantly decreased scar expansion and ventricular dilatation 25 days post-transplantation (4 weeks after MI). MMPs and TNF-α levels were reduced in the transplantation groups when compared to the group that was given an injection of medium only. Transplantation of TIMP-3 gene-transfected VSMCs was more effective in preventing progressive cardiac dysfunction, ventricular dilatation and in reducing MMP-2, MMP-9 and TNF-α levels when compared to the transplantation of untransfected VSMCs.ConclusionsTIMP-3 gene transfection was associated with attenuated left ventricular dilation and recovery of systolic function after MI compared with the control. TIMP-3 transfection enhanced the effects of transplanted VSMCs in rats by inhibiting matrix degradation and inflammatory cytokine expression, leading to improved myocardial remodelling.     

ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo

ADAM8 expression is increased in the interface tissue around a loosened hip prosthesis and in the pannus and synovium of patients with rheumatoid arthritis, but its potential role in these processes is unclear. ADAM8 stimulates osteoclast (OCL) formation, but the effects of overexpression or loss of expression of ADAM8 in vivo and the mechanisms responsible for the effects of ADAM8 on osteoclastogenesis are unknown. Therefore, to determine the effects of modulating ADAM expression, we generated tartrate‐resistant acid phosphatase (TRAP)–ADAM8 transgenic mice that overexpress ADAM8 in the OCL lineage and ADAM8 knockout (ADAM8 KO) mice. TRAP‐ADAM8 mice developed osteopenia and had increased numbers of OCL precursors that formed hypermultinucleated OCLs with an increased bone‐resorbing capacity per OCL. They also had an enhanced differentiation capacity, increased TRAF6 expression, and increased NF‐κB, Erk, and Akt signaling compared with wild‐type (WT) littermates. This increased bone‐resorbing capacity per OCL was associated with increased levels of p‐Pyk2 and p‐Src activation. In contrast, ADAM8 KO mice did not display a bone phenotype in vivo, but unlike WT littermates, they did not increase RANKL production, OCL formation, or calvarial fibrosis in response to tumor necrosis factor α (TNF‐α) in vivo. Since loss of ADAM8 does not inhibit basal bone remodeling but only blocks the enhanced OCL formation in response to TNF‐α, these results suggest that ADAM8 may be an attractive therapeutic target for preventing bone destruction associated with inflammatory disease. © 2011 American Society for Bone and Mineral Research.